别名:C14orf130应用:WB,IHC
反应种属:Human, Mouse
规格:50μl/100μl
| Description |
|---|
| Ubiquitination is an important mechanism through which three classes of enzymes act in concert to target short-lived or abnormal proteins for destruction. The three classes of enzymes involved in ubiquitination are the ubiquitin-activating enzymes (E1s), the ubiquitin-conjugating enzymes (E2s) and the ubiquitin-protein ligases (E3s). Ubr7 (ubiquitin protein ligase E3 component n-recognin 7), also known as C14orf130 or N-recognin-7, is a 425 amino acid protein that contains one UBR-type zinc finger and one PHD zinc finger. Participating in protein modification events within the N-end rule pathway, Ubr7 functions as an E3 ubiquitin-protein ligase that recognizes and binds proteins that contain destabilizing N-terminal residues, thereby leading to their ubiquitination and subsequent degradation. |
| Specification | |
|---|---|
| Aliases | C14orf130 |
| Swissprot | Q8N806 |
| WB Predicted band size | 48 kDa |
| Host/Isotype | Rabbit IgG |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human UBR7 |
| Formulation | pH7.4 PBS, 0.05% NaN3, 40% Glycerol |
| Application | |
|---|---|
| WB | 1/200-1/1000 |
| IHC | 1/30-1/150 |
| ELISA | 1/5000-1/10000 |
![]() |
Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: NIH/3T3 and 293T cell lysates, Primary antibody: P09385(UBR7 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds |
![]() |
The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09385(UBR7 Antibody) at dilution 1/30. (Original magnification: ×200) |
![]() |
The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P09385(UBR7 Antibody) at dilution 1/30. (Original magnification: ×200) |
本公司的所有产品仅用于科学研究或者工业应用等非医疗目的,不可用于人类或动物的临床诊断或治疗,非药用,非食用。
暂无评论
本公司的所有产品仅用于科学研究或者工业应用等非医疗目的,不可用于人类或动物的临床诊断或治疗,非药用,非食用。
中文



发表回复